Stock Analiz

Intellia Therapeutics, Inc. (NTLA) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Intellia Therapeutics’s revenue went from $16M in fiscal 2016 to $68M in fiscal 2025, growth of about 17.0% a year.

Net income in fiscal 2025 was -$413M, a net margin of -609.9%; the best year in this period was 2016 with -$32M.

Over the twelve months to September 30, 2026, revenue was $53M and net income -$426M.

Free cash flow was -$396M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 487597% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $16M162017: $26M172018: $30M182019: $43M192020: $58M202021: $33M212022: $52M222023: $36M232024: $58M242025: $68M25$68M
Net income
2016: -$32M162017: -$68M172018: -$85M182019: -$474M192020: -$134M202021: -$268M212022: -$474M222023: -$481M232024: -$519M242025: -$413M25-$413M
Free cash flow
2016: $30M162017: -$75M172018: -$68M182019: -$110M192020: -$53M202021: -$238M212022: -$347M222023: -$408M232024: -$355M242025: -$396M25-$396M
EPS (diluted)
2016: $-1420.00162017: $-1880.00172018: $-1980.00182019: $-2.11192020: $-2.40202021: $-3.78212022: $-6.16222023: $-5.42232024: $-5.25242025: $-3.8125$-3.81

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$53M$68M$58M$36M$52M$33M$58M$43M$30M$26M$16M
Gross profit—————$33M$58M$43M$30M——
Operating income-$434M-$441M-$534M-$515M-$458M-$268M-$137M-$106M-$91M-$70M-$32M
Net income-$426M-$413M-$519M-$481M-$474M-$268M-$134M-$474M-$85M-$68M-$32M
EPS (diluted)$-3.34$-3.81$-5.25$-5.42$-6.16$-3.78$-2.40$-2.11$-1980.00$-1880.00$-1420.00
R&D$335M$389M$466M$435M$420M$230M$150M$108M$89M$68M$32M
Revenue growth—+16.9%+59.6%−30.4%+57.7%−43.0%+34.5%+41.6%+16.5%+58.5%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$355M-$395M-$349M-$394M-$333M-$225M-$50M-$103M-$61M-$65M$36M
Capital spending-$3M-$1M-$6M-$14M-$14M-$13M-$4M-$7M-$6M-$10M-$6M
Free cash flow-$358M-$396M-$355M-$408M-$347M-$238M-$53M-$110M-$68M-$75M$30M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$63M$80M$154M$134M$91M$47M$20M$15M$17M$15M$7M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$450M$602M$912M$1.2B$749M$597M$280M$314M$341M$273M
Debt—$93M$210M$115M$131M$74M$39M$18M$0$0$0
Equity—$671M$872M$1.1B$1.2B$1.0B$527M$270M$278M$301M$210M
Total assets—$842M$1.2B$1.3B$1.5B$1.3B$676M$334M$347M$376M$299M
Shares (diluted)140M108M99M89M77M71M56M0M0M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—————100.0%100.0%100.0%100.0%——
Operating margin-821.2%-651.7%-923.1%-1420.5%-879.0%-810.4%-235.5%-246.8%-298.6%-266.3%-195.2%
Net margin-805.7%-609.8%-896.8%-1326.5%-909.8%-810.5%-231.5%-1100.1%-280.4%-258.6%-192.0%
FCF margin-677.1%-585.0%-612.8%-1124.9%-665.5%-719.4%-92.2%-255.3%-222.2%-288.6%181.7%
ROIC—-45.6%-39.0%-34.9%-26.5%-19.0%-19.1%-29.1%-25.8%-18.3%-15.3%
ROE—-61.5%-59.5%-45.8%-38.4%-25.8%-25.5%-175.7%-30.7%-22.5%-15.1%

Frequently asked questions

What is Intellia Therapeutics’s annual revenue?

$68M in fiscal 2025 and $53M over the twelve months to September 30, 2026.

How much profit does Intellia Therapeutics make?

Net income was -$413M in fiscal 2025 (net margin -609.9%).

Is Intellia Therapeutics’s revenue growing?

Yes: revenue rose 16.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.